A double-blind crossover trial comparing lorazepam at two dosage levels
with amylobarbitone supported previous reports of the effective anxiolytic
action of the drug. Evaluation of the patients' responses during each week
of treatment was based on a physician's weekly rating and on daily
self-rating by patients. The results were analyzed by sequential and
nonsequential analyses. The main side effect of the drug was drowsiness,
which occurred to a clinically significant degree among the high-dose group
of patients. The authors emphasize the value of two dosage trials,
particularly in devising subsequent flexible individual treatment
regimens.
Abstract Teaser